StockStory advises investors to avoid Teleflex, Enovis, and Ocular Therapeutix, citing concerns over profitability and capital efficiency despite broader sector gains. While healthcare stocks have risen 33.4% over the past six months, outperforming the S&P 500's 13.5% increase during the same period, the firm argues that heavy regulation and specific financial weaknesses make these three companies risky holdings.
Teleflex, which designs and supplies single-use medical devices for critical care and surgical procedures, has a market cap of $5.33 billion. The stock trades at $125.70, implying a forward price-to-earnings ratio of 13.6 times. StockStory identifies constant currency revenue growth as a key concern, noting that performance has disappointed over the past two years due to soft demand. Additionally, the company's earnings per share declined by 6.5% annually over the last five years, a rate that was worse than its revenue declines. The firm also points to shrinking returns on capital from a weak starting position, suggesting that both previous and ongoing investments are not yielding desired results.
Enovis focuses on orthopedic care devices, including joint replacement and rehabilitation tools, with a market cap of $1.05 billion. Trading at $18.26 per share, the stock has a forward price-to-earnings ratio of 5 times. According to StockStory, Enovis sales remained flat over the last five years, indicating a failure to expand during this cycle. Profitability eroded as earnings per share fell by 9.5% annually while revenue stayed flat, meaning each sale became less profitable. The firm characterizes the erosion of returns on capital from an already low base as value destruction by management's recent investments.
Ocular Therapeutix develops sustained-release eye treatments using its proprietary ELUTYX bioresorbable hydrogel technology, which gradually releases medication to potentially eliminate the need for monthly injections. The company has a market cap of $1.66 billion and trades at $7.68 per share, with a forward price-to-sales ratio of 29.5 times. StockStory highlights that sales tumbled by 7.7% annually over the last two years, suggesting market trends are working against the company. Furthermore, incremental sales over the last five years were less profitable, with earnings per share falling by 7.5% annually even as revenue grew. A significant reduction in free cash flow margin by 371.3 percentage points over the last five years suggests the company is consuming more capital to stay competitive.